Acasti Pharma appoints Michael L. Derby to Board of Directors

Grace Therapeutics, Inc.

Appointed effective March 24, 2022; term expires at 2022 annual meeting.
Receives standard non-employee director compensation: $30,000 annual cash plus equity awards.
Appointment fulfills undertaking from Grace Therapeutics acquisition (Aug 2021) to designate a Grace stockholder representative.
Derby has over 20 years biopharma experience; founded/co-founded seven companies including TardiMed Sciences.
Board determined Derby is independent under SEC and Nasdaq rules.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael L. Derby

Director

GRCE · Grace Therapeutics, Inc.

Effective: 2022-03-24
Filed: March 25, 2022, 7:59 PM ET

On March 24, 2022, the Board of Directors (the “Board”) of Acasti Pharma Inc. (the “Company”) appointed Michael L. Derby to the Board as a director, effective as of March 24, 2022, with a term expiring at the 2022 annual meeting of stockholders or until his successor is elected and qualified, or, if earlier, until his death, disability, resignation, disqualification, or removal from the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael L. Derby was appointed as Director at Grace Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 24, 2022, the Board of Directors (the “Board”) of Acasti Pharma Inc. (the “Company”) appointed Michael L. Derby to the Board as a director, effective as of March 24, 2022, with a term expiring at the 2022 annual meeting of stockholders or until his successor is elected and qualified, or, if earlier, until his death, disability, resignation, disqualification, or removal from the Board.

View on SEC.gov

Grace Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-004612

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.